A randomized, double blind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study.

Trial Profile

A randomized, double blind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Acronyms RINOMAX
  • Most Recent Events

    • 02 Apr 2018 Planned End Date changed from 1 Dec 2018 to 30 Jun 2020.
    • 02 Apr 2018 Planned primary completion date changed from 1 Aug 2018 to 30 Sep 2019.
    • 02 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top